Navigation Links
Corgenix Receives Additional European Patent, Announces Publication of Important Clinical Study on AtherOx(R) Technology
Date:6/22/2010

DENVER, June 22 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, announced today the issuance of one new European patent for the company's AtherOx® (oxLDL/B2GPI) technology and the publication of an important clinical trial studying oxLDL/B2GPI levels in patients with acute coronary syndrome (ACS).

"We are very pleased to announce these two very important accomplishments," said Douglass Simpson, President and CEO of Corgenix. "The newest patent expands our IP portfolio, and the acute coronary syndrome clinical trial reported remarkable results. Since cardiovascular disease is one of the world's leading causes of death, the early detection of atherosclerosis has become increasingly important, and we are optimistic about the ability of AtherOx to address this significant market."

The clinical trial was conducted at Saint Mary's Hospital in Waterbury, Conn., under the leadership of Thomas P. Greco, M.D.

European patent # EP 1 596 198 B, "Method of Measuring Oxidized LDL-Beta2-GP1-CRP Complex" was issued April 7, 2010. The patent is a method patent providing additional European protection to the components and assay procedure used to measure AtherOx complexes in biological samples. The latest patent adds to previous issued U.S. and European patents.

The clinical study, "Oxidized-LDL/B2-Glycoprotein I Complexes Are Associated With Disease Severity and Increased Risk for Adverse Outcomes in Patients With Acute Coronary Syndromes," was published in the American Journal of Clinical Pathology, 2010; 133:737-743.

"Our study showed that patients with severe coronary artery disease (CAD) had significantly higher mean levels of Oxidized-LDL/B2-Glycoprotein I (AtherOx) complexes," said Dr. Greco, principal investigator and lead author. "This supports the concept that AtherOx is associated with severity of CAD and demonstrates a 3.5-fold-increased risk for adverse outcomes."

Corgenix, in collaboration with Dr. Greco's and other groups, are investigating additional clinical populations to further assess the utility of AtherOx in determining the level of CAD risk and the means to modify its serum levels to reduce or prevent cardiovascular adverse outcomes.

Corgenix holds exclusive worldwide licensing rights for this technology outside of Japan. The technology is incorporated in the company's AtherOx product group, a next-generation technology to identify individuals at risk for developing atherosclerotic cardiovascular disease. In all countries where the use of products employing this technology has not been cleared, the products shall not be used for diagnostic use as the performance characteristics have not been established.

About AtherOx®

The AtherOx molecule is comprised of oxidized low-density lipoprotein (oxLDL) complexed with the plasma protein B2GPI. Although oxLDL has been implicated in cardiovascular disease, according to results published in the Annals of N.Y. Academy of Science (2007), determination of oxLDL/B2GPI complexes, rather than oxLDL alone, may be a more physiologic and accurate way of assessing the risk of progressive atherosclerotic cardiovascular disease in individuals with systemic lupus erythematosus and lupus-like disorders. Corgenix licensed this technology in 2002 and is developing additional products utilizing this unique platform.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for vascular diseases, immunology disorders, and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 52 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Corgenix to Exhibit AspirinWorks(R) Test at Pri-Med New York
2. Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents
3. Corgenix Secures $1,750,000 Asset Based Credit Facility Representing Initial Gross Proceeds of $1.109 Million
4. Corgenix Reports Third Quarter Fiscal 2009 Financial Results
5. Corgenix to Exhibit AspirinWorks(R) Test at ACC.09
6. Corgenix Reports Second Quarter Fiscal 2009 Financial Results
7. Corgenix to Host Conference Call to Discuss Second Quarter Results
8. Corgenix Signs Collaboration With Battelle
9. Corgenix Receives Two Additional Patents on AtherOx(R) Technology
10. Corgenix to Host Conference Call to Discuss First Quarter Results
11. Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... and LONDON , February 9, 2016 ... bio tech replace paper and protect IP ... electronic laboratory notebook (ELN) will be rolled out in ... research and development (R&D) and protect valuable IP. Users will ... follow a specific researcher or experiment as part of the ...
(Date:2/8/2016)... 2016 Should antibiotic bone cement products be ... prevent infection after standard total hip or knee replacement ... Institute have been fielding a lot lately. ... Line?" --> "Antibiotic Bone Cement: ... --> While there isn,t a simple answer, ...
(Date:2/8/2016)...  BioElectronics Corporation (OTC Pink: BIEL), the maker ... it is responding to a notice of an ... Exchange Commission posted on the agency website.  ... Board of BioElectronics Corporation and the Edward and ... Fuqua School of Business, Duke University.   ...
(Date:2/8/2016)... program for the development of future natural products for crop ... and development center in Israel and ... Stockton has a variety of products adapted to ... in more than 35 counties worldwide. ... product Timorex Gold ® is used to control a ...
Breaking Biology Technology:
(Date:1/27/2016)... 27, 2016  Rite Track, Inc. a leading semiconductor ... West Chester, Ohio announced today the acquisition ... based in Austin, Texas , will ... provide modifications, installations and technical support offerings for TEL ... PLUS, commented, "PLUS has provided world class service including ...
(Date:1/21/2016)... India , January 21, 2016 ... According to a new market research report "Emotion Detection ... and Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020", published by ... is expected to reach USD 22.65 Billion by ...
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized breaches ... to find new ways to ensure data security and ... iOS and Android that ties a ... transforming it into a hardware authorization token. Customer service ... their fingerprint on their KodeKey enabled device to verify ...
Breaking Biology News(10 mins):